pCPA

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of January 31, 2017. There are currently 38 negotiations underway with one new file (Keytruda (pembrolizumab)) added since the last update on December 31, 2016. There have been 133 joint negotiations completed with 2 files successfully negotiated since the last update of December 31, 2016: Blincyto…

The pan-Canadian Pharmaceutical Alliance (pCPA) Office released the monthly statistics for pCPA negotiations up to and including December 31, 2016.   To summarize, there were a total of 7 products with status changes: Three products added to the active list for a total of 43 active negotiations: Botox (multiple indications), Imbruvica (chronic lymphocytic leukemia/small lymphocytic leukemia), Rituxan SC. Two products concluded negotiations with an agreement: Grastofil, Metadol-D. Two products that…